Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
|Date:||Thursday, June 3, 2021|
|Time:||2:30 PM ET|
A replay of the presentation will be available on the “Events and Webcasts” section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
|Investor Relations Contact:||Company Contact:|
|Joyce Allaire||Dan Chevallard|
|LifeSci Advisors||Chief Operating Officer and Chief Financial Officer|
|[email protected]||[email protected]|
|(212) 915-2569||(858) 771-4193|
SOURCE Viracta Therapeutics, Inc.